Zapoteca portoricensis root crude methanol extract and its fractions normalizes aberrations associated with benign prostatic hyperplasia in rats

References

• Agbafor KN, Ogbanshi ME, Akubugwo EI. 2014. Phytochemical screening, hepatoprotective and antioxidant effect of leaf extract of Zapoteca portoricensis. Adv Biol Sci. 4:35–39.
   Google Scholar
• Agbo MO, Okoye FBC, Nwodo JN. 2010. In vivo anti-inflammatory effect of Zapoteca portoricensis. Int J Health Res. 3(1):29–35.
   Google Scholar
• Ajayi A, Abraham K. 2018. Understanding the role of estrogen in the development of benign prostatic hyperplasia. Afr J Urol. 24:93–97.
   Web of Science ®Google Scholar
• Akdogan M, Hassoun BS, Gurakar A, El-Sahwi K, Jazzar A, Wright H, Sebastian A, Nour B. 2002. Prostate-specific antigen levels among cirrhotic patients. Int J Biol Markers. 17(3):161–164.
   PubMed Web of Science ®Google Scholar
• Akinyemi RA, Huthman IO, Adesanya OA, Akpan HB, Adefule AK. 2012. Effect of the methanolic extract of Trichosanthes cucumerina seed (Snake Gourd/tomato) on experimentally-enlarged prostate gland in adult wistar rats. Res Rev J Med Health Sci. 1(1):10–17.
   Google Scholar
• Albers JJ, Warmick GR, Cheng MC. 1978. Determination of high density lipoprotein (HDL)-cholesterol. Lipids. 13:926–932.
   PubMed Web of Science ®Google Scholar
• Arthur JR, Boyne R. 1985. Superoxide dismutase and glutathione peroxidase activities in neutrophil from selenium deficient and copper deficient cattle. Life Sci. 36:1569–1575.
   PubMed Web of Science ®Google Scholar
• Asiedu B, Anang Y, Nyarko A, Doku DA, Amoah BY, Santa S, Ngala RA, Asare GA. 2017. The role of sex steroid hormones in benign prostatic hyperplasia. Aging Male. 20(1):17–22.
   PubMed Web of Science ®Google Scholar
• Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten O, Ozok Y, Dimovski A. 2006. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem. 39:176–179.
   PubMed Web of Science ®Google Scholar
• Babson AL, Greely SJ, Coleman CM, Philips GE. 1996. Phenolphthalein monophosphate as a substrate for serum alkaline phosphatase. Clin Chem. 12(18):482–490.
   Google Scholar
• Basatac C, Cicek MC. 2015. A huge benign prostatic hyperplasia presenting with renal failure. J Surg Case Rep. 6:1–2.
   Google Scholar
• Bonhorst CW, Mattice JJ. 1959. Colorimetric determination of selection in biological materials. Anal Chem. 31(12):2106–2107.
   Web of Science ®Google Scholar
• Boyd L. 2010. What causes BPH? Accessed August 10, 2019 www.livestrong.com/article/87491/causes-bph.
   Google Scholar
• Braeckman J, Denis L. 2017. Management of BPH then 2000 and now 2016: from BPH to BPO. Asian J Urol. 4:138–147.
   PubMed Web of Science ®Google Scholar
• Cannon GW, Getzenberg RH. 2008. Biomarkers for benign prostatic hyperplasia progression. Curr Urol Rep. 9(4):279–283.
   Google Scholar
• Chatelain C, Autet W, Brackman F. 1999. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology. 54:473–478.
   Web of Science ®Google Scholar
• Chelikani P, Fita I, Loewen P. 2004. Diversity of structures and properties among catalases. Cell Mol Life Sci. 61(2):192–208.
   PubMed Web of Science ®Google Scholar
• Chilumula R, Devaraj R, Sriramoju V, Dondapati T, Prakash A. 2018. Analysis of risk factors and outcome of renal failure in benign prostatic hyperplasia. J Clin Diagn Res. 12(1):PC01–PC03.
   Web of Science ®Google Scholar
• Chughtai B, Lee R, Te A, Kaplan S. 2011. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 13(3):147–150.
   PubMedGoogle Scholar
• Chung SD, Lin HC. 2011. Increased risk of benign prostatic enlargement among patients with liver cirrhosis: a nationwide population-based study. J Androl. 32(2):159–164.
   Google Scholar
• Coulson S, Rao A, Beck SL, Steels E, Gramotney H, Vitetta L. 2013. A phase II randomized double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: A herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complement Ther Med. 21:172–179.
   PubMed Web of Science ®Google Scholar
• Da Silva MHA, De Souza DB. 2019. Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. Res Rep Urol. 11:1–8.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Presicce F, Tubaro A. 2016. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nature Rev Urol. 13:613–626.
   PubMed Web of Science ®Google Scholar
• Dhingra N, Bhagwat D. 2011. Benign prostatic hyperplasia: An overview of existing treatment. Indian J Pharmacol. 43(1):6–11.
   PubMed Web of Science ®Google Scholar
• Disbrey BD, Rack JH. 1974. Histological laboratory methods. Edinburgh: Livingstone; p. 56–128.
   Google Scholar
• Drury RAB, Wallington EA. 1967. Careton’s histological technique, 4th ed. London: Oxford University Press; p. 120–123.
   Google Scholar
• Duru RC, Njoku OU, Maduka IC, Ugonabo MC, Ugwueme FO. 2015. Artherogenic lipid markers and testosterone levels in Nigerian men with prostate disorders. Asian Pacific J Health Sci. 2:48–55.
   Google Scholar
• Ejike CE, Ezeanyika LUS. 2008. Metabolic syndrome in sub-Saharan Africa: smaller twin of a regions prostatic disease. Int Urol Nephrol. 40(4):909–920.
   Web of Science ®Google Scholar
• Ejike CE, Ezeanyika LUS. 2011. Management of experimental BPH in rats using a food based therapy containing Telfairia occidentalis seeds. AJTCAM. 8(4):398–340.
   Google Scholar
• Elkahwaji JE. 2013. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol. 5:1–10.
   Google Scholar
• Erhirhie EO, Ilodigwe EE, Ajaghaku DL, Mbagwu IS, Moke EG. 2015. Toxicity evaluation of a commercial herbal preparation used in Nigeria. Eur J Med Plant. 5(2):176–190.
   Google Scholar
• Esterbauer H, Schaur RJ, Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 11(1):81–128.
   PubMed Web of Science ®Google Scholar
• Ezeanyika LUS, Ejike CECC, Obidoa O, Elom SO. 2006. Prostate disorders in an apparent normal Nigerian population: prevalence. Biokemistri. 18(2):127–132.
   Google Scholar
• Foo KT. 2017. Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol. 4(3):152–157.
   PubMed Web of Science ®Google Scholar
• Fossati P, Prencipe L, Berti G. 1980. Use of 3, 5-dichloro- 2-hydroxybenzenesulfonic acid/4-ami nophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem. 26(2):227–231.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. J Clin Chem. 18:499–502.
   Google Scholar
• Gasco M, Villegas L, Yucra S, Rubio J, Gonzales GF. 2007. Dose–response effect of Red Maca (Lepidium meyenii) on benign prostatic hyperplasia induced by testosterone enanthate. Phytomedicine. 14:460–464.
   PubMed Web of Science ®Google Scholar
• Hagberg KW, Divan HA, Persson R, Nickel JC, Jick SS. 2016. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice research Datalink. Br Med J. 354:i4823.
   PubMed Web of Science ®Google Scholar
• Hassan AU, Hassan G, Zubeida ZR. 2013. Aims and objectives of histological studies of prostate. Uni J Clin Med. 1(2):13–21.
   Google Scholar
• Ikeyi AP, Ezeanyika LUS, Alumanah EO, Okagu IU. 2019. Proximate and phytochemical compositions, and toxicity studies on Zapoteca portoriscensis root methanol extract and its fractions. Pharmacologyonline. 2019(1):50–56.
   Google Scholar
• Iweala EEJ, Ogidigo JO. 2015a. Prostate specific antigen, antioxidant and hematological parameters in prostatic rats fed Solanum macrocarpon L. leaves. Asian J Biol Sci. 8:30–41.
   Google Scholar
• Iweala EEJ, Ogidigo JO. 2015b. Effect of Celosia argentea F. Cristata (L.) Schinz. on prostate specific antigen, antioxidant status and hematological parameters in rats induced with benign prostate hyperplasia. Asian J Biochem. 10:42–51.
   Google Scholar
• Joshua PE, Ezugwu CH, Chilaka FC, Nwodo OFC, Dasofunjo K, Ezugwu MU. 2018. Effect of ethanol extract of Zapoteca portoricensis stem on testosterone-induced benign prostate hyperplasia (BPH) in adult male albino rats. Australian J Basic Applied Sci. 12(12):9–18.
   Google Scholar
• King KJ, Wootton IDP. 1959. Microanalysis in medical biochemistry. New York, NY: McGrew Hill; p. 14.
   Google Scholar
• Krušlin B, Tomas D, Džombeta T, Milković-Periša M, Ulamec M. 2017. Inflammation in prostatic hyperplasia and carcinoma-basic scientific approach. Front Oncol. 7:77.
   PubMed Web of Science ®Google Scholar
• Liu J, Fang T, Li M, Song Y, Li J, Xue Z, Li J, Bu D, Liu W, Zeng Q, et al. 2019. Pao pereira extract attenuates testosterone-induced benign prostatic hyperplasia in rats by inhibiting 5α-reductase. Sci Rep. 9:19703.
   Web of Science ®Google Scholar
• Liu Y, Zuckier LS, Ghesani NV. 2010. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res. 30:369–374.
   Web of Science ®Google Scholar
• Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, Joshi PH, Kulkarni KR, Mize PD, Kwiterovich PO, et al. 2013. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. CME J Am Coll Cardiol. 62(8):732–739.
   Web of Science ®Google Scholar
• Mbaka G, Anunobi C, Ogunsina S, Osiagwu D. 2017. Histomorphological changes in induced benign prostatic hyperplasia with exogenous testosterone and estradiol in adult male rats treated with aqueous ethanol extract of Secamone afzelii. Egyptian J Basic Applied Sci. 4:15–21.
   Google Scholar
• Mbaka GO, Ogbonnia SO, Olawunmi O. 2013. The effects of ethanol extract of Raphia hookeri seed on exogenous testosterone and estradiol induced benign prostatic hyperplasia in adult male rats. J Morphol Sci. 30(4):235–243.
   Google Scholar
• Meludu SC, Ezenwelu VI, Manafa PO, Onah CE, Ekuma-Okereke O. 2017. Biochemical characteristics of liver enzymes, prolactin, zinc and selenium in benign prostatic hyperplasia and cancer of the prostate patients attending urology clinic at Nnamdi Azikiwe University Teaching Hospital, Nnewi. IJIR. 3(7):223–232.
   Google Scholar
• Mohamed DA, Rashed MM, Shallan M, Fouda K, Hanna LM. 2016. Amelioration of benign prostate hyperplasia in rats through plant foods. Int J Pharmacogn Phytochem Res. 8(12):2063–2070.
   Google Scholar
• Moke EG, Ilodigwe EE, Okonta JM, Emudainohwo JOT, Ajaghaku DL, Erhirhie OE, Chinwuba P, Ahante E. 2015. Antidiabetic activity and toxicity evaluation of aqueous extracts of Spondias mombin and Costus afer on wistar rats. British J Pharm Res. 6(5):333–342.
   Google Scholar
• Nandecha C, Nahata A, Dixit VK. 2010. Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. Cur Therapeut Res. 71:331–343.
   PubMed Web of Science ®Google Scholar
• Nandeesha H, Koner BC, Dorairajan LN, Sen SK. 2006. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 370:89–93.
   PubMed Web of Science ®Google Scholar
• Nwodo NJ, Okoye FBC, Lai D, Debbab A, Brun R, Proksch P. 2014. Two trypanocidal Dipeptides from the roots of Zapoteca portricensis (Fabaceae). Molecules. 19:5470–5477.
   PubMed Web of Science ®Google Scholar
• Nwodo NJ, Uzochukwu IC. 2008. Studies on anti-inflammatory and antimicrobial activities of crude methanol extracts of Zapoteca portoricensis. Jacq. H. Hernandez. Rec Prog Med Plants. 19:61–69.
   Google Scholar
• Ochei J, Kolhatkar A. 2008. Medical laboratory sciences, theory and practice. New Delhi: Tata McGraw-Hill Publishing Co. Ltd; p. 321–324.
   Google Scholar
• Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ. 2007. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate. 67:1061–1069.
   Web of Science ®Google Scholar
• Park BK, Kim CW, Kwon JE, Negi M, Koo YT, Lee SH, Baek DH, Noh YH, Kang SC. 2019. Effects of Lespedeza cuneate aqueous extract on testosterone-induced prostatic hyperplasia. Pharm Biol. 57(1):90–98.
   Web of Science ®Google Scholar
• Pudasaini S, Subedi N, Shrestha NM. 2019. Evaluation of prostate specific antigen levels and its correlation with histopathological findings. J Pathol Nepal. 9:1485–1489.
   Google Scholar
• Rastrelli G, Vignozzi L, Corona G, Maggi M. 2019. Testosterone and benign prostatic hyperplasia. Sex Med Rev. 7(2):259–271.
   PubMed Web of Science ®Google Scholar
• Reitman S, Frankel D. 1957. A colometric method of determination of serum glutamic oxaloacetic and glutamic pyruvic transaminase. Am J Pathol. 28:56–62.
   Web of Science ®Google Scholar
• Roehrborn CG. 2008. Pathology of benign prostatic hyperplasia. Int J Impot Res. 20:S11–S18.
   PubMed Web of Science ®Google Scholar
• Roeschlau P, Bernt E, Gruber WA. 1974. Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem. 12(5):226–228.
   PubMedGoogle Scholar
• Rule AD, Jacobson DJ, Roberts RO, Girman CJ, McGree ME, Lieber MM, Jacobsen SJ. 2005a. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int. 67:2376–2382.
   PubMed Web of Science ®Google Scholar
• Rule AD, Lieber MM, Jacobsen SJ. 2005b. Is benign prostatic hyperplasia a risk factor for chronic renal failure? J Urol. 173(3):691–696.
   Web of Science ®Google Scholar
• Sinha KA. 1972. Colorimetric assay of catalase. Ann Biochem. 47(2):389–394.
   Google Scholar
• Steemkamp V. 2003. Phytomedicines for the prostate. Fitoterapia. 74(6):545–552.
   Web of Science ®Google Scholar
• Sun H, Li TJ, Sun LN, Qiu Y, Huang BB, Yi B, Chen WS. 2008. Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats. J Ethnopharmacol. 115:203–208.
   Web of Science ®Google Scholar
• Tewari R, Mohini C, Shankar MN, Apul G, Divakar D, Madhu M, Singh R. 2014. Significant association of metabolic indices, lipid profile, and androgen levels with prostate cancer. Asian Pac J Cancer Prev. 15(22):9841–9846.
   Google Scholar
• Tewari R, Prabhat P, Natu SM. 2011. Association of benign prostatic hyperplasia (BPH) with metabolic syndrome (MS) and its components: A growing dilemma. J Men’s Health. 8(2):66–71.
   Google Scholar
• Tietz NW. 1983. Methods for the determination of ascorbic acid. In: Kay D, Kilmer D, editor. Textbook of clinical chemistry. Philadelphia: W.B. Saunders Company; p. 932–933.
   Google Scholar
• Tietz NW. 1995. Clinical guide to laboratory test, 3rd ed. Philadelphia: W.B. Saunders Company; p. 518–519.
   Google Scholar
• Tietz NW, Pruden EL, Siggaard-Andersen O. 1976. Electrolytes, blood gases and acid-base balance. In: Tietz NW, editor. Textbook of clinical chemistry. Philadelphia: W.B. Saunders Company; p. 1188–1215.
   Google Scholar
• Trost L, Saitz TR, Hellstrom WJG. 2013. Side effects of 5-alpha reductase inhibitors: A comprehensive review. Sex Med Rev. 1(1):24–41.
   PubMedGoogle Scholar
• Ukwe CV, Ubaka CM, Adibe MO, Okonkwo CJ, Akah PA. 2010. Antiulcer activity of roots of zapoteca portoricensis (fam. fabiaceae). JBCP. 1(3):183–186.
   Google Scholar
• Veeresh BSV, Veeresh B, Patil AA, Warke YB. 2010. Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol. 626:262–265.
   Web of Science ®Google Scholar
• Vyas N, Argal A. 2012. Nephroprotective effect of ethanolic extract of roots and oleanolic acid isolated from roots of Lantana camas. Int J Pharmacol Clin Sci. 1:54–60.
   Google Scholar
• Wallin B, Rosengren B, Shertzer HG, Camejo G. 1993. Lipoprotein oxidation and measurement of TBARS formation in single microlitre Figure, its use for evaluation of antioxidants. Anal Biochem. 208:10–15.
   PubMed Web of Science ®Google Scholar